Jade Biosciences JBIO
NASDAQ JBIO
$19.91 +0.06 (+0.30%)
As of: Sep 4, 2026 · 3:59 PM EDT

Jade Biosciences (JBIO) EV to CFO (2021 - 2026)

Analysis

Jade Biosciences (JBIO) EV to CFO (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Jade Biosciences 1.21 Bn 1.21 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -21.79
Mar 31, 2026 -15.85
Dec 31, 2025 -16.50
Sep 30, 2025 -3.74
Jun 30, 2025 -5.21
Mar 31, 2025 -129.99
Dec 31, 2024 -110.80
Sep 30, 2024 -288.94
Mar 31, 2024 -1,211.69
Dec 31, 2023 -1,477.50
Sep 30, 2023 -826.06
Jun 30, 2023 -1,092.70
Mar 31, 2023 -1,515.08
Dec 31, 2022 -1,696.88
Sep 30, 2022 -1,436.04
Jun 30, 2022 -1,473.81
Mar 31, 2022 -2,714.44
Dec 31, 2021 -374.67
Sep 30, 2021 -2,718.92
Jun 30, 2021 -53.65